Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women

Table 1 Distribution of the Proportion of Days Covered (PDC) according to cardiovascular drug class

Cardiovascular drug class	ATC code	N (total)	Mean	Lower Quartile	Median	Upper Quartile	% of compliant patients^a
Diuretics	C03	8655	67.8	48.5	83.0	92.9	54.3
Beta blocking agents	C07	14,687	79.8	74.8	89.6	95.6	70.5
Calcium channel blockers	C08	9744	75.5	70.7	89.3	95.6	67.6
Agents acting on the renin–angiotensin system	C09	22,507	83.9	82.5	91.0	95.6	78.9
Lipid-modifying agents	C10	20,917	75.2	67.1	85.8	93.2	61.7
Platelet aggregation inhibitors excl. heparin	B01AC	9226	69.1	57.5	79.5	88.5	49.2

^aPatients were considered to be adherent with a drug class if their PDC for that class was ≥ 0.8

ISSN: 1741-7015